Vitara Biomedical has filed a notice of an exempt offering of securities to raise $49,999,190.00 in New Equity Investment.
According to filings with the U.S. Securities and Exchange Commission, Vitara Biomedical is raising up to $49,999,190.00 in new funding. The federal securities law requires the notice to be filed by companies that have sold securities without registration under the Securities Act of 1933 in an offering made under Rule 504 or 506 of Regulation D or Section 4(a)(5) of the Securities Act. A company must file this notice within 15 days after the first sale of securities in the offering. For this purpose, the date of first sale is the date on which the first investor is irrevocably contractually committed to invest. Each issuer of securities that sells its securities in reliance on an exemption provided in Regulation D or Section 4(a)(5) of the Securities Act of 1933 must file this notice containing the information requested with the U.S. Securities and Exchange Commission (SEC) and with the state(s) requiring it. If more than one issuer has sold its securities in the same transaction, all issuers should be identified in this filing with the SEC.
About Vitara Biomedical
At Vitara, we are working to offer preterm newborns and their families a lifetime of possibilities. We seek to transform neonatal care by protecting more preterm infants and improving their quality of life. Vitara’s mission is to transform neonatal care. Vitara’s vision is to offer newborns and their families a lifetime of possibilities. When a premature baby is born into the world, they’re faced with severe physiological challenges. With the help of Vitara’s technology, we hope to provide a comfortable and stable environment for the baby to acclimate outside of the womb while continuing to develop.
To learn more about Vitara Biomedical, visit http://www.vitara.com/
Vitara Biomedical Linkedin Page: https://www.linkedin.com/company/vitara-biomedical/
Contact:
Bernard Lyons, Interim Chief Executive Officer
267-518-6300
https://www.linkedin.com/in/bernard-lyons-8327477/
SOURCE: http://www.intelligence360.io
Copyright (c) 2024 SI360 Inc. All rights reserved.